Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of SRP-3D (DA) in Healthy Subjects
NCT05484414Phase 1Completed
- Sponsor
- South Rampart Pharma
- Start
- Dec 2021
- Primary completion
- Nov 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SRP-001 in pain (2 arms), sponsored by South Rampart Pharma. Primary endpoint: Treatment-related adverse events at 30 days. Started Dec 2021; status: completed.
02
Drugs
SRP-001
03
Conditions
pain
Beyond the preview
Go deeper on NCT05484414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05484414.